2024/07/29 17:35:19 | |
---|---|
Price | |
8.705 EUR | |
Difference | 0.29% (0.03) |
ISIN | DE0005664809 |
Symbol | EVT |
Exchange | Xetra |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 1,543 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 8.58 EUR |
High | 8.775 EUR |
Low | 8.455 EUR |
Close (prev. day) | 8.68 EUR |
VWAP | 8.64863 EUR |
Volume (pcs) | 538,718 |
Trading volume | 4,659,173.08 |
Number of trades | 1,288 |
Last size | 148,589 |
Related Futures | 24 |
Related Options | - |
Date | Headline | Download | |
2024/07/24 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings |
2024/07/29 17:35:19 | |
---|---|
Price | |
8.705 EUR | |
Difference | 0.29% (0.03) |
ISIN | DE0005664809 |
Symbol | EVT |
Exchange | Xetra |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 1,543 EUR |
Benchmark | GERMANY DAX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 8.58 EUR |
High | 8.775 EUR |
Low | 8.455 EUR |
Close (prev. day) | 8.68 EUR |
VWAP | 8.64863 EUR |
Volume (pcs) | 538,718 |
Trading volume | 4,659,173.08 |
Number of trades | 1,288 |
Last size | 148,589 |
6m | 1Y | 3Y | |
Perf (%) | -39.50% | -61.87% | -74.93% |
Perf (abs.) | -5.67 | -14.08 | -25.94 |
Beta | 1.78 | 1.85 | 1.10 |
Volatility | 75.07 | 63.22 | 53.35 |
Ø price 5 days | Ø volume 5 days (pcs.) | 8.732 EUR (589,474) |
Ø price 30 days | Ø volume 30 days (pcs.) | 8.845 EUR (1,049,136) |
Ø price 100 days | Ø volume 100 days (pcs.) | 10.524 EUR (1,423,299) |
Ø price 250 days | Ø volume 250 days (pcs.) | 14.968 EUR (892,811) |
YTD High | date | 21.420 EUR (2024/01/03) |
YTD Low | date | 7.215 EUR (2024/06/17) |
52 Weeks High | date | 24.390 EUR (2023/08/01) |
52 Weeks Low | date | 7.215 EUR (2024/06/17) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Xetra | 2024/07/29 | 17:35 | 8.705 EUR | 4.66 | 1,288 |
Vienna Stock Exchange | 2024/07/29 | 17:32 | 8.69 EUR | 0.00 | 5 |
Tradegate | 2024/07/29 | 22:26 | 8.65 EUR | 1.75 | 320 |
Stuttgart | 2024/07/29 | 21:45 | 8.69 EUR | 0.15 | 78 |
SIX Swiss Exchange | 2023/04/12 | 17:35 | 27.76 CHF | 0.00 | 1 |
Munich | 2024/07/29 | 16:38 | 8.58 EUR | 0.03 | 2 |
London Stock Exchange European Trade Reporting | 2024/07/29 | 17:30 | 8.685 EUR | 0.00 | 2 |
Hanover | 2024/07/29 | 08:16 | 8.465 EUR | 0.00 | 3 |
Hamburg | 2024/07/29 | 08:16 | 8.465 EUR | 0.00 | 3 |
Frankfurt | 2024/07/29 | 21:49 | 8.675 EUR | 0.01 | 4 |
FINRA other OTC Issues | 2024/07/11 | 20:04 | 10.13 USD | 0.02 | 17 |
Euronext Milan MTF Trading After Hours | 2024/06/19 | 18:05 | 7.055 EUR | 0.00 | 2 |
Euronext Milan MTF Global Equity Market | 2024/07/29 | 17:44 | 8.68 EUR | 0.00 | 1 |
Duesseldorf | 2024/07/29 | 19:31 | 8.655 EUR | 0.00 | 5 |
Berlin | 2024/07/29 | 21:52 | 8.685 EUR | 0.00 | 18 |
EVOTEC SE |
- - |
Manfred Eigen Campus, Essener Bogen 7 - 22419 Hamburg |
Telefon: +49-40-56081-0 |
Fax: +49-40-56081-222 |
E-mail: info@evotec.com |
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany. |
Christian Wojczewski | Chairman of Managing Board |
Cord Dohrmann | Member of Executive Committee |
Craig Johnstone | Member of Executive Committee |
Matthias Evers | Member of Executive Committee |
Aurelie Dalbiez | Member of Executive Committee |
Laetitia Rouxel | Member of Executive Committee |
Iris Löw-Friedrich | Chairman of Supervisory Board |
Constanze Ulmer-Eilfort | Member of Supervisory Board |
Duncan McHale | Member of Supervisory Board |
Camilla Languille | Member of Supervisory Board |
Roland Sackers | Member of Supervisory Board |
Wesley Wheeler | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer